Entyvio Continues to Show Benefits for Inflammatory Bowel Disease
A closer look at the data
The results that they gathered had been reported in 33 studies from May 2014 to January 2017. Overall, these studies looked at 2,857 patients who were treated with vedolizumab. In this patient sample, 1,532 had Crohn’s and 829 had UC. The follow-up periods ranged from 0.5 to 18 months.
